by Jordana Choucair | Aug 18, 2022 | Life Sciences
The Food and Drug Administration (FDA) approved Bluebird Bio Inc.’s Zynteglo gene therapy. The approval gives patients suffering from a rare genetic blood disorder called beta-thalassemia a possible cure, at a hefty price. Bluebird, which has priced the...
by Jordana Choucair | Aug 18, 2022 | Opioid/Substance Use Disorders
A federal judge yesterday ordered CVS, Walgreens, and Walmart to pay $650 million to two Ohio counties, claiming the way they distributed opioids caused severe harm and created a public nuisance. The judge’s verdict is the first federal ruling to put a price tag on...
by Jordana Choucair | Aug 18, 2022 | Opioid/Substance Use Disorders
The Wisconsin Legislature’s Joint Committee on Finance rejected Governor Tony Evers’ spending plan for $31 million in settlement funds to combat the state’s opioid epidemic. The plan proposed using the money to increase the availability of NARCAN, invest in new...
by Jordana Choucair | Aug 18, 2022 | Payers
J.D. Power’s annual study of Medicare Advantage (MA) plans found that members are satisfied with the plans, but say mental health and substance use disorder (SUD) treatment coverage is lacking. Ninety-one percent members said they have enough coverage for...
by Jordana Choucair | Aug 18, 2022 | Payers
CMS announced that providers will no longer need to fill out certificates of medical necessity (CMN) and durable medical equipment information forms (DIF) starting in 2023. The agency is making the change in an effort to ease administrative burden. “Through...
Recent Comments